EpimAb Biotherapeutics Appoints Jerry Su, Ph.D. as Chief Technology Officer
EpimAb Biotherapeutics , a clinical stage biotech company specializing in bispecific antibodies, today announced the appointment of Jerry Su, Ph.D. as the Chief Technology Officer of EpimAb.
- EpimAb Biotherapeutics , a clinical stage biotech company specializing in bispecific antibodies, today announced the appointment of Jerry Su, Ph.D. as the Chief Technology Officer of EpimAb.
- Dr. Su joined EpimAb in December 2019 as Senior VP, CMC and led the completion of EpimAbs early CMC development facility in Suzhou BioBay.
- Since he joined EpimAb, Jerry contributed significantly to the organizational growth of EpimAb by successfully completing our fully functional CMC development and manufacturing facility in Suzhou BioBay ahead of plan, said Dr. Chengbin Wu, founder and CEO of EpimAb Biotherapeutics.
- EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company with research and manufacturing facilities in Shanghai and Suzhou, China.